Ocera Therapeutics — Tranzyme — Investor Presentation (November 2012)
13 slides from Ocera Therapeutics's investor presentation, Nov 28, 2012
Slide 1: Emerging Leader in Upper GI Motility Therapeutics
Emerging Leader in Upper GI Motility Therapeutics NASDAQ: TZYM. www.tranzyme.com November 28, 2012
Slide 2: Safe Harbor Statement
Safe Harbor Statement Certain items in this presentation and other matters discussed today or answers that may be given to questions asked could constitute forward-looking statements, including statements regarding the progress and timing of clinical trials, the safety and efficacy of our product ca
Slide 3: TZP-102-G003 Phase 2b Top-Line Results
TZP-102-G003 Phase 2b Top-Line Results
Slide 4: Trial Design
TZP-102 Phase 2b Trial Design 12-week, double-blind, US & EU, placebo-controlled trial Once daily oral administration of 10mg, 20mg TZP-102 or placebo 201 patients; 43 sites Efficacy assessment: Primary Endpoint: Change from baseline in the average GSDD composite score at end of treatment Gastropare
Slide 5: GSDD Week
TZP-102 Phase 2b Results: GSDD Week 4
Slide 6: GSDD Week
TZP-102 Phase 2b Results: GSDD Week 12
Slide 7: Mean Change in Symptoms at Week 4
TZP-102 Phase 2b Results: Mean Change in Symptoms at Week 4 Mean Change in Daily Diary Individual Symptom Score from Baseline to End of Week 4 Symptom Placebo (n=64) 10mg (n=66) 20mg (n=65) All TZP-102 Doses (n=131) Nausea -0.96 -1.25 -0.93 -1.09 Early Satiety -0.84 -1.20 -0.96 -1.08 Bloating -0.96
Slide 8: Mean Change in Symptoms at Week 12
TZP-102 Phase 2b Results: Mean Change in Symptoms at Week 12 Mean Change in Daily Diary Individual Symptom Score from Baseline to End of Week 12 Symptom Placebo (n=64) 10mg (n=66) 20mg (n=65) All TZP-102 Doses (n=131) Nausea -1.53 -1.84 -1.37 -1.61 Early Satiety -1.41 -1.76 -1.47 -1.62 Bloating -1.5
Slide 9: GCSI Week
TZP-102 Phase 2b Results: GCSI Week 4
Slide 10: GCSI Week
TZP-102 Phase 2b Results: GCSI Week 12
Slide 11: Safety
TZP-102 Phase 2b Safety Both doses well tolerated No significant differences between the doses or dose-dependent trends No significant metabolic changes throughout 12-week treatment period Body weight Glucose HbA1c
Slide 12: DIGEST Trial (2nd Phase 2b)
TZP-102 DIGEST Trial (2nd Phase 2b) Primary Endpoint: Change from baseline in the average GSDD composite score at end of treatment 12-week, double-blind, US & EU, placebo-controlled trial Three times daily oral administration of 10mg TZP-102 or placebo before meals ~120 patients; ~35 sites Enrollmen
Slide 13: Next Steps
TZP-102 Next Steps Interim data review (including futility analysis) planned for DIGEST before year-end Approximately 60 patients (30 per arm) data through treatment week 4 Enrollment completion: Q1 2013 Top-line data expected: H1 2013 EOP2 meeting with the FDA: H2 2013